knowledge -WSS

knowledge

author：focus 2025-09-29 23:28:09 - browse：31668

Kidney transplants are the most common organ transplant procedure in the U.S., with 25,000 taking place in 2022. But for patients who receive new kidneys, the transplant is often followed by severe lifelong challenges, many of which are linked to the immunosuppression drug regimen required after surgery to ensure the body does not reject the new organ. These treatments have side effects and toxicities that impact patients’ long-term health, and even survival, leading to a transplant failure rate of 30-50% at the 10-year mark.

Now a new trial sponsored by Medeor Therapeutics, the results of which were presented Thursday at the American Society of Nephrology (ASN) Kidney Week 2023 Annual Meeting, offers hope that stem cell therapy may help patients discontinue their immunosuppressant regime within a year of the transplant.

“The ability to get a transplant without being on lifelong immunosuppression is kind of a dream in transplant, so I can see why this would generate a lot of excitement,” said Sommer Gentry, a professor of surgery at New York University, who was not involved in the study and was not at the actual presentation, but reviewed the trial’s presentation slides.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： New guidelines on severe brain injury complicate already difficult decisions

leisure time

WSS

The strategy behind pharma's lawsuits over drug pricing reform

SAMSHA loosens regulations on methadone treatment centers

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

What is the Wagner Group? The 'brutal' Russian military unit in Ukraine

What is the Wagner Group? The 'brutal' Russian military unit in Ukraine

Ask STAT: What do you want to know about ChatGPT in medicine?

leisure time

knowledge

hotspot

BioMarin wins approval for gene therapy to treat hemophilia A

Donald Trump's relentless attacks on special counsel Jack Smith

The cancer drug shortage isn’t new — and neither are the solutions

New guidelines on severe brain injury complicate already difficult decisions

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

ARCH Venture Partners is raising $3 billion for a life sciences fund

Trump demands the U.S. pay no more for drugs than other countries … again

SAMSHA loosens regulations on methadone treatment centers

Apple is now the first public company to be valued at $3 trillion

Medicare drug price negotiation’s day in court

focus

The strategy behind pharma's lawsuits over drug pricing reform

Disclosing genetic information: not as worrisome as once feared

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

Cybersecurity threat forces Lurie Children's to take systems offline

#NeedHerScience: shining a light on gender disparities in medicine

Ask STAT: What do you want to know about ChatGPT in medicine?

hotspot

leisure time

Wikipedia

explore